Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
SUM149PT Pictilisib
0.31623
pan PI3K
PI3K/mTOR
 0.8933 -0.00096
SUM149PT Pictilisib
1.0
pan PI3K
PI3K/mTOR
 0.8145 -0.00115
SUM149PT Pictilisib
3.1623
pan PI3K
PI3K/mTOR
 0.6738 0.00649
SUM149PT Pictilisib
10.0
pan PI3K
PI3K/mTOR
 0.3333 0.03571
SUM149PT Ceritinib
0.001
ALK
RTK
 0.9820 0.00096
SUM149PT Ceritinib
0.0031623
ALK
RTK
 0.9871 0.00696
SUM149PT Ceritinib
0.01
ALK
RTK
 1.0285 0.00078
SUM149PT Ceritinib
0.031623
ALK
RTK
 0.9905 0.00343
SUM149PT Ceritinib
0.1
ALK
RTK
 0.9679 0.00231
SUM149PT Ceritinib
0.31623
ALK
RTK
 0.9324 0.00545
SUM149PT Ceritinib
1.0
ALK
RTK
 0.8066 0.01922
SUM149PT Ceritinib
3.1623
ALK
RTK
 0.0015 0.38249
SUM149PT Ceritinib
10.0
ALK
RTK
 -0.4396 0.67528
SUM149PT Neratinib
0.00031623
EGFR/HER2
RTK
 1.0066 0.00828
SUM149PT Neratinib
0.001
EGFR/HER2
RTK
 1.0130 -0.00371
SUM149PT Neratinib
0.0031623
EGFR/HER2
RTK
 1.0286 -0.00420
SUM149PT Neratinib
0.01
EGFR/HER2
RTK
 0.9286 -0.00306
SUM149PT Neratinib
0.031623
EGFR/HER2
RTK
 0.6667 0.01042
SUM149PT Neratinib
0.1
EGFR/HER2
RTK
 0.4200 0.03559
SUM149PT Neratinib
0.31623
EGFR/HER2
RTK
 0.2648 0.07508
SUM149PT Neratinib
1.0
EGFR/HER2
RTK
 0.2009 0.08112
SUM149PT Neratinib
3.1623
EGFR/HER2
RTK
 0.1521 0.10580
SUM149PT Tivantinib
0.001
MET
RTK
 1.0137 0.00034
SUM149PT Tivantinib
0.0031623
MET
RTK
 1.0076 0.00196
SUM149PT Tivantinib
0.01
MET
RTK
 0.9904 0.00336